ClinicalTrials.gg
Active, not recruitingNCT05561595HEARTSUpdated Sep 16, 2026

Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma

An interventional study of Healing HEARTS and Peer Support in Obesity, Skin Disease and Cancer, sponsored by University of Florida. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by University of Florida · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Obesity by University of Florida — 5 open to participants now, 6 under way, none of them phase 3. Obesity · University of Florida.

Planned enrollment
10th of 34
195 · median 55
Started
2024
with 3 others
No phase
29 of 37
5 open now
Registered
29th of 37
by date

Among the 37 studies in Obesity by University of Florida, this one is the 10th largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2024, is one of 29 with no phase, and was the 29th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 37 studies in Obesity by University of Florida are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Obesity by University of Florida, or all of them as a file.
02

Study summary

Stigma due to health conditions increases disease burden and adversely impacts health. The internalization of health-related stigma is associated with impaired mental health and quality of life. The current project will test the effects of a novel, transdiagnostic, group counseling intervention, and peer support, to determine the optimal method for helping patients cope with health-related stigma, reducing its internalization, and enhancing patient quality of life.

Read the detailed description

This randomized controlled trial (RCT) will test in a sample of 195 patients with high levels of internalized health-related stigma the effects of a novel transdiagnostic intervention designed to help patients cope with this stigma and to reduce its internalization. Participants will be randomly assigned to one of three intervention conditions: (1) a group-based counseling intervention designed to target internalized health-related stigma, delivered virtually (i.e., via telehealth); (2) a general peer support group conducted via telehealth without a targeted stigma intervention; or (3) a waitlist control group. The counseling and peer support conditions will provide 12 weekly group sessions, followed by 2 every other week sessions and 2 monthly sessions (16 sessions total over the course of 26 weeks, or 6 months). Participants across all conditions will complete outcome assessment visits at baseline/randomization, week 12, and week 26. The waitlist control group will receive 12 weeks of the group counseling intervention (condition #1) after completing the week 26 assessment. The primary trial outcome will be the change in internalized stigma from baseline to week 12 (following the most intensive part of the intervention). Change in internalized stigma from baseline to week 26 will be a secondary outcome to determine lasting effects of the intervention in a "maintenance" period with less frequent intervention. Other secondary outcomes will include depression, anxiety, stress, coping, and health-related quality of life (HRQOL)

03

Conditions studied

  • Obesity
  • Skin Disease
  • Cancer
  • HIV
  • Diabetes
  • Chronic Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Currently residing in the United States
  • At least one of the following stigmatized health conditions:
  • Obesity (or high body weight that negatively affects health)
  • Skin disease (including but not limited to psoriasis, eczema, or vitiligo)
  • Cancer (including but not limited to lung, breast, cervical, colorectal, gynecologic, prostate, or head and neck; including individuals in remission)
  • Type 1 or type 2 diabetes
  • Chronic pain
  • Reported internalization of health-related stigma, as determined by a pre-specified cutoff score on internalized stigma measure and confirmed by interview

Participants must have availability to attend weekly virtual group meetings for 12 weeks, followed by every-other-week and monthly meetings through 26 weeks, in the evening on a specified weekday. Participants must be willing to actively participate and share information about themselves in the group meetings.

Participants must be able to read, comprehend, and speak English in order to participate in group sessions and complete study questionnaires.

Participation requires an electronic device (computer, tablet, or phone) with video capabilities and internet, wi-fi, or cellular data in order to attend group sessions and complete study questionnaires. Individuals who do not have such devices or internet access will still be eligible to participate. In such cases, screening procedures will be conducted by phone, and randomized participants will be provided with web cameras or internet-enabled devices (and/or provided with pre-paid cellular data) to facilitate participation.

Exclusion criteria

Exclusion Criteria:

  • Current or recent (e.g., past 3 months) receipt of psychotherapy or a psychosocial or peer support intervention (exceptions may be made if therapy or support is not focused on health conditions and is unlikely to affect internalized health-related stigma; e.g., family or marriage counseling, religious study groups, etc.)
  • Psychiatric hospitalization in the past 6 months
  • Recent (e.g., past 3 months, approximately) change in medications taken for psychiatric reasons
  • Current, active suicidal thoughts or suicide attempt within the past year
  • Current or past thought disorder or psychosis, or unmanaged bipolar disorder
  • Current alcohol/substance use disorder that requires immediate treatment
  • Health-related stigma due primarily to mental illness or substance use, or due to health conditions not specified in inclusion criteria.
  • No reported internalization of health-related stigma and/or score below pre-specified cutoff on internalized stigma measure
  • Unwilling or unable to complete study procedures

Participants with severe progression of disease (e.g., end-of-life) or who are undergoing acute, intensive treatment (such as chemotherapy or radiation therapy) will not be eligible to participate due to expected impacts on HRQOL and greater needs for psychological support than the intervention is intended to provide. Such participants may be eligible after completion of acute treatment or if severe symptoms remit and/or prognosis improves.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
195 participants (estimated)

Study arms

  • Experimental
    Healing HEARTS Intervention

    The Healing Health-Related Stigma (Healing HEARTS) intervention will provide group telehealth sessions adapted from prior disease-specific interventions for internalized stigma and from standard techniques and structures used in evidence-based cognitive-behavioral therapies. Fifty-minute sessions will be delivered weekly for 12 weeks, followed by 2 every-other-week and 2 monthly sessions. Groups will consist of approximately 8-10 participants and will be led by a doctoral- or masters-level clinician in clinical or counseling psychology or social work. Handouts and homework assignments will be used as part of the group meetings. All group sessions will be conducted remotely using telehealth technology.

    Behavioral: Healing HEARTS

  • Active comparator
    Peer Support

    The peer support condition will provide group telehealth sessions without any tailored stigma content. Group sessions will be 50 minutes and will meet weekly for 12 weeks, followed by 2 every-other-week and 2 monthly sessions. Groups will consist of approximately 8-10 participants and will be led by a doctoral- or masters-level clinician in clinical or counseling psychology or social work. All group sessions will be conducted remotely using telehealth technology.

    Behavioral: Peer Support

  • No intervention
    Waitlist Control

    The waitlist control group will not receive any active intervention until after completing week 12 and week 26 assessments. Participants will receive periodical updates and reminders from study staff to enhance retention. After assessments are completed, participants will be provided with 12 weeks of the Healing HEARTS intervention.

Interventions

  • BehavioralHealing HEARTS

    Session topics will include: psychoeducation; myths and stereotypes; cognitive distortions and restructuring; coping strategies; interpersonal effectiveness; self-efficacy; mindfulness and self-compassion; acceptance and positive self-image; disclosure and finding support; stigma in health care; and empowerment and advocacy.

  • BehavioralPeer Support

    Peer support groups will cover general topics such as symptom management, stress, and social support. Stigma will not be a formal topic of discussion, and group leaders will be trained to avoid initiating conversations about stigma; however, to capture realistic discussions in peer support groups, participants will not be prohibited from discussing the topic should they bring it up.

06

What researchers measure

Primary outcomes

  1. Change in Internalized Health-Related Stigma Scale score at Week 12

    Estimated mean change score for the total scale (primary outcome) and three subscales (Perceived and Anticipated Stigma, Stereotype Application and Self-Devaluation, and Stigma Resistance); scale scores are averaged and range from 1-7, with higher scores indicating greater internalized health-related stigma.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change in Internalized Health-Related Stigma Scale score at Week 26

    Estimated mean change score for the total scale (primary outcome) and three subscales (Perceived and Anticipated Stigma, Stereotype Application and Self-Devaluation, and Stigma Resistance); scale scores are averaged and range from 1-7, with higher scores indicating greater internalized health-related stigma.

    Time frame: Baseline to Week 26

  2. Change in Internalized Shame Scale score at Week 12

    Estimated mean change score for two subscales: Shame (summed scores range from 0-96, higher scores indicate greater shame) and Self-Esteem (summed scores range from 0-24, higher scores indicate higher self-esteem).

    Time frame: Baseline to Week 12

  3. Change in Internalized Shame Scale score at Week 26

    Estimated mean change score for two subscales: Shame (summed scores range from 0-96, higher scores indicate greater shame) and Self-Esteem (summed scores range from 0-24, higher scores indicate higher self-esteem).

    Time frame: Baseline to Week 26

  4. Change in UCLA Loneliness Scale score at Week 12

    Estimated mean change score, with summed scores ranging from 20-80 (higher scores indicate greater loneliness/isolation).

    Time frame: Baseline to Week 12

  5. Change in UCLA Loneliness Scale score at Week 26

    Estimated mean change score, with summed scores ranging from 20-80 (higher scores indicate greater loneliness/isolation).

    Time frame: Baseline to Week 26

  6. Change in Patient Health Questionnaire-9 score at Week 12

    Estimated mean change score, with summed scores ranging from 0-27 (higher scores indicate greater severity of depression symptoms).

    Time frame: Baseline to Week 12

  7. Change in Patient Health Questionnaire-9 score at Week 26

    Estimated mean change score, with summed scores ranging from 0-27 (higher scores indicate greater severity of depression symptoms).

    Time frame: Baseline to Week 26

  8. Change in Generalized Anxiety Disorder-7 Questionnaire score at Week 12

    Estimated mean change score, with summed scores ranging from 0-21 (higher scores indicate greater severity of generalized anxiety).

    Time frame: Baseline to Week 12

  9. Change in Generalized Anxiety Disorder-7 Questionnaire score at Week 26

    Estimated mean change score, with summed scores ranging from 0-21 (higher scores indicate greater severity of generalized anxiety).

    Time frame: Baseline to Week 26

  10. Change in Severity Measure for Social Anxiety Disorder score at Week 12

    Estimated mean change score, with summed scores ranging from 0-40 (higher scores indicate greater severity of social anxiety).

    Time frame: Baseline to Week 12

  11. Change in Severity Measure for Social Anxiety Disorder score at Week 26

    Estimated mean change score, with summed scores ranging from 0-40 (higher scores indicate greater severity of social anxiety).

    Time frame: Baseline to Week 26

  12. Change in 4-item Perceived Stress Scale score at Week 12

    Estimated mean change score, with summed scores ranging from 0-16 (higher scores indicate greater perceived stress).

    Time frame: Baseline to Week 12

  13. Change in 4-item Perceived Stress Scale score at Week 26

    Estimated mean change score, with summed scores ranging from 0-16 (higher scores indicate greater perceived stress).

    Time frame: Baseline to Week 26

  14. Change in General Self-Efficacy Scale score at Week 12

    Estimated mean change score, with summed scores ranging from 10-40 (higher scores indicate greater self-efficacy).

    Time frame: Baseline to Week 12

  15. Change in General Self-Efficacy Scale score at Week 26

    Estimated mean change score, with summed scores ranging from 10-40 (higher scores indicate greater self-efficacy).

    Time frame: Baseline to Week 26

  16. Change in Revised Illness Perceptions Questionnaire scores at Week 12

    Estimated mean change scores on four subscales: Consequences, Personal Control, Illness Coherence, and Emotional Representations. Scores for each subscale are averaged, with ratings ranging from 1-5, and higher scores Indicating greater perceived consequences, control, understanding, and emotional impacts of health conditions, respectively.

    Time frame: Baseline to Week 12

  17. Change in Revised Illness Perceptions Questionnaire scores at Week 26

    Estimated mean change scores on four subscales: Consequences, Personal Control, Illness Coherence, and Emotional Representations. Scores for each subscale are averaged, with ratings ranging from 1-5, and higher scores Indicating greater perceived consequences, control, understanding, and emotional impacts of health conditions, respectively.

    Time frame: Baseline to Week 26

  18. Change in SF-12v2 scores at Week 12

    Estimated mean change scores in mental and physical health component t-scores, with a population mean score of 50 and standard deviation of 10 (higher scores indicate better mental and physical health-related quality of life, respectively).

    Time frame: Baseline to Week 12

  19. Change in SF-12v2 scores at Week 26

    Estimated mean change scores in mental and physical health component t-scores, with a population mean score of 50 and standard deviation of 10 (higher scores indicate better mental and physical health-related quality of life, respectively).

    Time frame: Baseline to Week 26

  20. Change in CDC Healthy Days Core Measure at Week 12

    Estimated mean change scores in items assessing the number of unhealthy days due to physical and mental health, respectively (range 0-30 days), the number of days of impairment due to poor health (0-30 days), and an unhealthy days index score of total combined physically and mentally unhealthy days (0-30 days).

    Time frame: Baseline to Week 12

  21. Change in CDC Healthy Days Core Measure at Week 26

    Estimated mean change scores in items assessing the number of unhealthy days due to physical and mental health, respectively (range 0-30 days), the number of days of impairment due to poor health (0-30 days), and an unhealthy days index score of total combined physically and mentally unhealthy days (0-30 days).

    Time frame: Baseline to Week 26

Other outcomes

  1. Change in Brief COPE scores at Week 12

    Estimated mean change in scores on the following subscales (all with two items rated 1-4, summed to produce scores ranging from 2-8, with higher scores indicating greater use of the respective coping strategy): self-distraction; active coping; denial; substance use; use of emotional support; use of instrumental support; behavioral disengagement; venting; positive reframing; planning; humor; acceptance; religion; and self-blame. Coping strategies may also be analyzed by grouping coping strategies into three broad categories and averaging scores for items within each category: active coping (active coping, positive reframing, planning, humor, acceptance); disengaged coping (self-distraction, denial, substance use, behavioral disengagement, venting, self-blame); and support coping (emotional support, instrumental support, religion).

    Time frame: Baseline to Week 12

  2. Change in Brief COPE scores at Week 26

    Estimated mean change in scores on the following subscales (all with two items rated 1-4, summed to produce scores ranging from 2-8, with higher scores indicating greater use of the respective coping strategy): self-distraction; active coping; denial; substance use; use of emotional support; use of instrumental support; behavioral disengagement; venting; positive reframing; planning; humor; acceptance; religion; and self-blame. Coping strategies may also be analyzed by grouping coping strategies into three broad categories and averaging scores for items within each category: active coping (active coping, positive reframing, planning, humor, acceptance); disengaged coping (self-distraction, denial, substance use, behavioral disengagement, venting, self-blame); and support coping (emotional support, instrumental support, religion).

    Time frame: Baseline to Week 26

  3. Change in 6-Item Social Support Questionnaire scores at Week 12

    Estimated mean change scores on two subscales assessing (1) the average number of support persons (N subscale) and (2) the average level of satisfaction with social support (the S subscale, with scores ranging from 1-6, and higher scores indicating greater satisfaction with social support).

    Time frame: Baseline to Week 12

  4. Change in 6-Item Social Support Questionnaire scores at Week 26

    Estimated mean change scores on two subscales assessing (1) the average number of support persons (N subscale) and (2) the average level of satisfaction with social support (the S subscale, with scores ranging from 1-6, and higher scores indicating greater satisfaction with social support).

    Time frame: Baseline to Week 26

  5. Treatment Acceptability ratings at Week 12

    To assess treatment acceptability, participants in the two active treatment groups (not the waitlist control group) rate from 1-7 how acceptable and helpful the program was, how much they liked the program, and how satisfied they were; scores for these 4 items are averaged. Participants also rate (1-7) how likely they would be to recommend the program to others and the extent to which they learned new things, changed their attitudes about themselves, and the program helped with managing their health conditions. Participants also rate how much they learned and used specific skills from the program; these item responses are averaged on a 1-7 scale for learned skills and on a 1-5 scale for used skills. Higher scores indicate greater treatment acceptability.

    Time frame: Week 12

  6. Treatment Acceptability ratings at Week 26

    To assess treatment acceptability, participants in the two active treatment groups (not the waitlist control group) rate from 1-7 how acceptable and helpful the program was, how much they liked the program, and how satisfied they were; scores for these 4 items are averaged. Participants also rate (1-7) how likely they would be to recommend the program to others and the extent to which they learned new things, changed their attitudes about themselves, and the program helped with managing their health conditions. Participants also rate how much they learned and used specific skills from the program; these item responses are averaged on a 1-7 scale for learned skills and on a 1-5 scale for used skills. Higher scores indicate greater treatment acceptability.

    Time frame: Week 26

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Data will be shared via the National Institute of Mental Health (NIMH) Data Archive (NDA; https://nda.nih.gov).

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be deposited to NDA starting 12 months after the award begins and will be deposited every six months thereafter following the usual NDA data submission dates of January 15th and July 15th.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 26 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2022
First posted
Sep 30, 2022
StartActual
Oct 3, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05561595
Responsible party
Sponsor
First posted
Sep 30, 2022
Start date
Oct 3, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 16, 2026

Study contacts

Rebecca Pearl, PhD
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion